CFDE Data Portal | Search RUNX1-AS1

	Label	Description
	RUNX1-AS1 Gene (Entity type)	ENSG00000286153 - RUNX1 antisense RNA 1
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS

RUNX1-AS1

ENSG00000286153 - RUNX1 antisense RNA 1

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.